Compare ADMA Biologics Inc (ADMA) vs Remitly Global Inc (RELY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Remitly Global Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Remitly Global Inc trades at $23.07 (market cap $5.08B). The key difference: Remitly Global Inc is far larger — about 2.4× ADMA Biologics Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | RELY | |
|---|---|---|
Market Cap | $2.13B | $5.08B |
Sector | Health | Technology |
52-Week High | $20.38 | $24.28 |
52-Week Low | $7.60 | $12.20 |
Enterprise Value | $2.20B | $4.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
RELY trades at $24.13, up 1.6% on the day, with strong bullish technical signals from moving averages and a consensus analyst price target of $25.67. The company shows accelerating revenue growth, reaching $1.64 billion in 2025, and has achieved profitability with net income of $67.93 million. Recent news highlights expansion into Canada and new business features driving investor optimism.
Outlook remains positive due to sustained revenue growth and market expansion, though high valuation multiples and overbought RSI levels pose near-term risks. The stock offers growth potential in digital payments but faces execution and competitive pressures in the remittance space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
